NFKB1 and metabolic dysfunction-associated steatotic liver disease: In the development of a range of liver diseases, one of the most remarkable molecular changes driving the NAFLD–LF–HCC axis is the NF-κB signaling pathway, so anti-inflammatory processes play a crucial role in all three disease stages.